CompletedNCT03709940
Brain Features Linked to ADHD Treatment Response
About this title
Read the official source — NCT03709940Researchers studied MPH to find out how it affected ADHD symptoms in people with ADHD.
Medication studyAges 18–45United Kingdom
Understand this study
What did researchers investigate?
Researchers studied MPH to find out how it affected ADHD symptoms in people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
- Listed locations
- LondonSee all locations and recruitment
Study information
Study start dateStarted: May 3, 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- King's College London
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Locations
- United Kingdom
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT03709940
- Official title
Show the full official title
Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD): a Biomarker to Predict Treatment Response
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
London
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied MPH to find out how it affected ADHD symptoms in people with ADHD.
Who is behind this study?
The study sponsor is King's College London, a university.
Did this study involve medication?
Yes. The study involved medication, including MPH.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Atomoxetine or placebo to maintain response in adult ADHD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...